These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30556650)

  • 1. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
    Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
    Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII-Fc Activates Natural Killer Cells
    Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
    Front Immunol; 2021; 12():692157. PubMed ID: 34262568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.
    Driessler F; Miguelino MG; Pierce GF; Peters RT; Sommer JM
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):540-550. PubMed ID: 28486277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
    Leksa NC; Chiu PL; Bou-Assaf GM; Quan C; Liu Z; Goodman AB; Chambers MG; Tsutakawa SE; Hammel M; Peters RT; Walz T; Kulman JD
    J Thromb Haemost; 2017 Jun; 15(6):1167-1179. PubMed ID: 28397397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIII Fc for the treatment of haemophilia A.
    Hermans C; Mancuso ME; Nolan B; Pasi KJ
    Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
    St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
    J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.
    Kis-Toth K; Rajani GM; Simpson A; Henry KL; Dumont J; Peters RT; Salas J; Loh C
    Blood Adv; 2018 Nov; 2(21):2904-2916. PubMed ID: 30396910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.